conducted trial and error and dedicated studies while gathering each one's excellent techniques, knowledge, etc., such as those from basic reproduction studies of primates including cynomolgus monkey, the concept of the pathological conditions of human endometriosis etc., and their assessment and clinical management (laparoscopic surgery and observation, MRI (magnetic resonance imaging) assessment, etc.), then completing the present invention.

In one aspect, the present disclosure refers to the use of an isolated anti-IL-8 antibody that binds to human IL-8 in the preparation of a composition for treating or preventing an IL-8-related disease, wherein the IL-8-related disease is selected from the group consisting of endometriosis; adenomyosis; dysmenorrhea; adhesion; fibrotic diseases; pain in endometriosis, adenomyosis, or dysmenorrhea; infertility; and pain resulting from adhesion, fibrosis, or inflammation; and wherein the anti-IL-8 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 34 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 35.

In a further aspect, the present disclosure refers to the use of an isolated anti-IL-8 antibody that binds to human IL-8 in the preparation of a composition for treating or preventing an IL-8-related disease, wherein the IL-8-related disease is selected from the group consisting of endometriosis; adenomyosis; dysmenorrhea; adhesion; fibrotic diseases; pain in endometriosis, adenomyosis, or dysmenorrhea; infertility; and pain resulting from adhesion, fibrosis, or inflammation, and wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 37 and a light chain comprising the amino acid

CLAIMS

1. Use of an isolated anti-IL-8 antibody that binds to human IL-8 in the preparation of a composition for treating or preventing an IL-8-related disease,
wherein the IL-8-related disease is selected from the group consisting of endometriosis; adenomyosis; dysmenorrhea; adhesion; fibrotic diseases; pain in endometriosis, adenomyosis, or dysmenorrhea; infertility; and pain resulting from adhesion, fibrosis, or inflammation; and
wherein the anti-IL-8 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 34 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 35.

2. Use of an isolated anti-IL-8 antibody that binds to human IL-8 in the preparation of a composition for treating or preventing an IL-8-related disease,
wherein the IL-8-related disease is selected from the group consisting of endometriosis; adenomyosis; dysmenorrhea; adhesion; fibrotic diseases; pain in endometriosis, adenomyosis, or dysmenorrhea; infertility; and pain resulting from adhesion, fibrosis, or inflammation, and
wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 38.

3. The use of any one of claim 1 or 2, wherein the fibrotic disease is selected from the group consisting of fibrosis in endometriosis or adenomyosis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, psoriasis, hepatic fibrosis, renal fibrosis, and pulmonary fibrosis.

THERAPEUTIC OR PREVENTIVE COMPOSITIONS FOR IL-8-RELATED DISEASES

ABSTRACT

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

(Fig. 34-2 for publication)